Patent 10864199
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (2)
Group view →Specific litigation cases in our database that name US patent 10864199. The free-form analysis below may also discuss cases beyond this list.
- Veloxis Pharmaceuticals AS v. Zydus Cadila et al.filed Apr 23, 20261:26-cv-00467Delaware District CourtOpen
Defendants: Zydus Cadila and Zydus Lifesciences Ltd
Other patents asserted: 11419823, 8685998, 8664239, 11123331, 12403095, 10166190, 11110081, 12083103, 9549918
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
- 1:22-cv-00909Delaware District Courtterminated Jan 24, 2024dismissed with prejudice
Defendants: Accord Healthcare and Intas
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
US patent 10864199 has been involved in litigation. Here's a summary of known cases:
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Accord Healthcare & Intas
- Jurisdiction: Delaware District Court
- Case Number: 1:22-cv-00909
- Filing Date: The consent judgment was filed on January 24, 2024.
- Current Status/Outcome: Dismissed with prejudice via a consent judgment. This means Veloxis cannot refile these specific claims, and Accord loses the right to relitigate its invalidity and non-infringement counterclaims in Delaware on these patents against this ANDA product. The consent judgment enjoins Accord and Intas from infringement until the expiration of the patents-in-suit.
It's important to note that US patent 10864199 is part of a larger patent family related to extended-release tacrolimus formulations, and Veloxis has asserted multiple patents in its portfolio in litigation against generic challengers.
Generated 6/1/2026, 12:48:44 AM